The Emerging Use of Chemotherapy-Free Regimens in Adults With Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia

Abstract: Before the development of tyrosine kinase inhibitors (TKIs), the outcome of patients with a diagnosis of Philadelphia chromosome (Ph)–positive acute lymphoblastic leukemia was dismal. Combinations […]

Hyper-CVAD–Based Regimens in Adult Patients With Acute Lymphoblastic Leukemia

H&O How was the hyper-CVAD regimen originally used? EJ The hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) regimen was developed by Kantarjian and colleagues at MD […]

Hem/Onc News

Tagraxofusp-erzs Approved in Blastic Plasmacytoid Dendritic Cell Neoplasm The US Food and Drug Administration (FDA) approved tagraxofusp-erzs (Elzonris, Stemline) on December 21 for blastic plasmacytoid dendritic […]

Management of Acute Lymphoblastic Leukemia in Young Adults

Abstract: Substantial interest in acute lymphoblastic leukemia (ALL) in young adults (YAs) and investigations focused on this patient population have resulted in therapeutic advancements that […]

Philadelphia Chromosome–Like Acute Lymphoblastic Leukemia: Progress in a New Cancer Subtype

Abstract: Philadelphia chromosome–like (Ph-like) acute lymphoblastic leukemia (ALL) is a newly described, high-risk subtype of B-cell ALL. It is characterized by a gene expression profile […]

Treatment of Acute Lymphoblastic Leukemia in Older Adults: Now and the Future

Abstract: Acute lymphoblastic leukemia (ALL) is an uncommon disease with poor outcomes in older patients. Although intensive chemotherapy can induce complete responses in older patients, […]

Should Treatment of Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Be Intensive?

Clinical Advances in Hematology & Oncology Volume 14, Issue 11, November 2016 Counterpoints: Approximately 20% to 30% of adults diagnosed with acute lymphoblastic leukemia are positive […]